BioCentury | Jun 5, 2020
Finance

With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients

...Hepatocyte growth factor/scatter factor MET (c-MET; HGFR) - c-Met receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Hepatocyte...
BioCentury | May 6, 2020
Regulation

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

...HGFR) - c-Met receptor tyrosine kinase RET - Ret proto-oncogene Lauren Martz, Senior Editor capmatinib (INC280, incb28060) Novartis AG c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR)...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear Therapeutics Inc. Medimetriks Pharmaceuticals Inc. Otsuka Pharmaceutical Co. Ltd. Merck KGaA Jazz Pharmaceuticals plc Forge Therapeutics Inc. Roche c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) GABA...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BioCentury | Sep 12, 2019
Distillery Therapeutics

ROS1 and pan-NTRK inhibitor for NSCLC resistant to Xalkori

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) A dual ROS1 and pan-NTRK inhibitor from Daiichi Sankyo Co. Ltd. could treat Xalkori crizotinib-resistant NSCLC, which has been linked to ROS1 mutations. In vitro high...
BioCentury | Sep 6, 2019
Company News

Sept. 6 Company Quick Takes: Soliris patents denied; plus Novartis, Roche, Lilly and Boehringer

...Other), Anti-PDL1 (Other) Vargatef, nintedanib (BIBF 1120, ofev, BIBF1120) Alexion Pharmaceuticals Inc. Boehringer Ingelheim GmbH Eli Lilly and Co. Novartis AG Roche c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Complement...
BioCentury | Jun 4, 2019
Clinical News

June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

...tepotinib. Brian Moy, Assistant Editor capmatinib (INC280, incb28060) tepotinib (MSC2156119J) Aadi Bioscience Inc. American Society of Clinical Oncology ASCO Incyte Corp. Merck KGaA Novartis AG c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) nab-sirolimus...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...Therapeutics Co. Ltd. Johnson & Johnson MacroGenics Inc. Memorial Sloan Kettering Cancer Center Miltenyi Biotec GmbH Suzhou Alphamab Co. Ltd. Zhejiang University c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Cytotoxic...
BioCentury | Jun 1, 2019
Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

...Clinical Oncology AstraZeneca plc Daiichi Sankyo Co. Ltd. IQVia Holdings Inc. Mount Sinai Hospital Pfizer Inc. Roche Sema4 U.S. Food and Drug Administration (FDA) c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Cyclin...
Items per page:
1 - 10 of 186